First RSV vaccine Arexvy Inj lands in Korea
By Whang, byung-woo | translator Alice Kang
24.12.27 05:10:28
가나다라
0
Approved as a respiratory syncytial virus vaccine in Korea for those over 60 years of age
Expanded influence in the U.S. and Europe by increasing its eligible subjects to those aged 50 to 59 years old
First RSV-LRTD prevention vaccine to grow to No. 1 in the global market
Arexvy, GSK's global sales driver as a No. 1 adult RSV vaccine, is set to launch in Korea.
▲Pic of Arexvy
GSK Korea's Respiratory Syncytial Virus (RSV) vaccine Arexvy was recently approved by the Ministry of Food and Drug Safety (MFDS) for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older. After setting the milestone as the first RSV-LRTD vaccine, the vaccine was approved by the U.S. Food and Drug Administration (FDA) in May last year and then extended to those 50-59 years of age in June.
The approval was based on results from two Phase III studies, RSV OA=ADJ-006 and RSV OA=ADJ-004, in adults aged 60 years and older.
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)